{"id":326341,"date":"2026-10-26T11:35:31","date_gmt":"2026-10-26T06:05:31","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=326341"},"modified":"2026-10-26T11:35:31","modified_gmt":"2026-10-26T06:05:31","slug":"cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/","title":{"rendered":"3 Cardiovascular and CNS Leader, Chronic Therapy Specialist and Largest Domestic Pharma Seller Stocks With a Strong Future Roadmap: Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma: ROE of 11.7% to 25.5% and FY22 to FY26 revenue CAGR of 12.4% to 22.9%. Prices as of 23 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three branded prescription drug maker stocks to watch are Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma. Their return on equity ranges from 11.7% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 22.9%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Eris Lifesciences has the fastest revenue growth at 22.9% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Branded prescription drug maker stocks let investors follow companies that serve a growing part of the Indian economy. Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma cover a cardiovascular and central nervous system leader, a chronic therapy specialist and one of the largest domestic pharma sellers.<\/p>\n<p>This list covers three branded prescription drug maker stocks with complete current figures: Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#What_Are_Branded_Prescription_Drug_Maker_Stocks\" title=\"What Are Branded Prescription Drug Maker Stocks?\">What Are Branded Prescription Drug Maker Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#Branded_Prescription_Drug_Maker_Stocks_at_a_Glance\" title=\"Branded Prescription Drug Maker Stocks at a Glance\">Branded Prescription Drug Maker Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#Why_Do_Branded_Prescription_Drug_Maker_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Branded Prescription Drug Maker Stocks Have a Strong Roadmap in India?\">Why Do Branded Prescription Drug Maker Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#Why_Torrent_Pharmaceuticals_Features_Among_These_Branded_Prescription_Drug_Maker_Stocks\" title=\"Why Torrent Pharmaceuticals Features Among These Branded Prescription Drug Maker Stocks\">Why Torrent Pharmaceuticals Features Among These Branded Prescription Drug Maker Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#Why_Eris_Lifesciences_Features_Among_These_Branded_Prescription_Drug_Maker_Stocks\" title=\"Why Eris Lifesciences Features Among These Branded Prescription Drug Maker Stocks\">Why Eris Lifesciences Features Among These Branded Prescription Drug Maker Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#Why_Mankind_Pharma_Features_Among_These_Branded_Prescription_Drug_Maker_Stocks\" title=\"Why Mankind Pharma Features Among These Branded Prescription Drug Maker Stocks\">Why Mankind Pharma Features Among These Branded Prescription Drug Maker Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#Torrent_Pharmaceuticals_vs_Eris_Lifesciences_vs_Mankind_Pharma_on_Key_Financials\" title=\"Torrent Pharmaceuticals vs Eris Lifesciences vs Mankind Pharma on Key Financials\">Torrent Pharmaceuticals vs Eris Lifesciences vs Mankind Pharma on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#Key_Risks_to_Check_Before_Investing_in_Branded_Prescription_Drug_Maker_Stocks\" title=\"Key Risks to Check Before Investing in Branded Prescription Drug Maker Stocks\">Key Risks to Check Before Investing in Branded Prescription Drug Maker Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#Final_Thoughts_on_Branded_Prescription_Drug_Maker_Stocks\" title=\"Final Thoughts on Branded Prescription Drug Maker Stocks\">Final Thoughts on Branded Prescription Drug Maker Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#What_are_branded_prescription_drug_maker_stocks\" title=\"What are branded prescription drug maker stocks?\">What are branded prescription drug maker stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#Which_branded_prescription_drug_maker_stocks_are_covered_in_this_list\" title=\"Which branded prescription drug maker stocks are covered in this list?\">Which branded prescription drug maker stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#Why_do_branded_prescription_drug_maker_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do branded prescription drug maker stocks have a strong future roadmap in India?\">Why do branded prescription drug maker stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#How_has_Torrent_Pharmaceuticals_performed_financially\" title=\"How has Torrent Pharmaceuticals performed financially?\">How has Torrent Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#How_has_Eris_Lifesciences_performed_financially\" title=\"How has Eris Lifesciences performed financially?\">How has Eris Lifesciences performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#How_has_Mankind_Pharma_performed_financially\" title=\"How has Mankind Pharma performed financially?\">How has Mankind Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#What_risks_should_investors_check_before_buying_branded_prescription_drug_maker_stocks\" title=\"What risks should investors check before buying branded prescription drug maker stocks?\">What risks should investors check before buying branded prescription drug maker stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic-pharma-seller-stocks-roadmap-northstar-list\/#Is_this_list_of_branded_prescription_drug_maker_stocks_investment_advice\" title=\"Is this list of branded prescription drug maker stocks investment advice?\">Is this list of branded prescription drug maker stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Branded_Prescription_Drug_Maker_Stocks\"><\/span><strong>What Are Branded Prescription Drug Maker Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Branded prescription drug maker stocks are listed drug makers that sell prescription and consumer health brands to doctors and patients across India. Their earnings depend on brand strength, field force reach, new launches and the share of chronic therapies.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Branded_Prescription_Drug_Maker_Stocks_at_a_Glance\"><\/span><strong>Branded Prescription Drug Maker Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/torntpharm\/torrent-pharmaceuticals-ltd-share-price-today\">Torrent Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,524.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">173,079<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">80.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1.79<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/eris\/eris-lifesciences-ltd-share-price-today\">Eris Lifesciences<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,095.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,618<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.60<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/mankind\/mankind-pharma-ltd-share-price-today\">Mankind Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,212.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">93,014<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">45.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.39<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Eris Lifesciences trades at a P\/E below the industry P\/E, while Torrent Pharmaceuticals and Mankind Pharma trade above it, which reflects the growth the market already expects. Readers comparing branded prescription drug maker stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in branded prescription drug maker stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Branded_Prescription_Drug_Maker_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Branded Prescription Drug Maker Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Branded prescription drug maker stocks have a strong roadmap in India because rising healthcare access, longer life spans and a growing chronic disease burden keep lifting demand for trusted branded medicines.<\/p>\n<ul>\n<li><strong>Chronic therapies.<\/strong> Long-term treatments for heart, diabetes and stomach care give repeat demand.<\/li>\n<li><strong>Field force reach.<\/strong> Large doctor networks help new launches scale.<\/li>\n<li><strong>Consumer health.<\/strong> Trusted over-the-counter brands widen the customer base.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Torrent_Pharmaceuticals_Features_Among_These_Branded_Prescription_Drug_Maker_Stocks\"><\/span><strong>Why Torrent Pharmaceuticals Features Among These Branded Prescription Drug Maker Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the branded prescription drug maker stocks on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.<\/p>\n<p>Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%.<\/p>\n<p>In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P\/E of 80.3, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.<\/p>\n<p><strong>What to watch:<\/strong> Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Eris_Lifesciences_Features_Among_These_Branded_Prescription_Drug_Maker_Stocks\"><\/span><strong>Why Eris Lifesciences Features Among These Branded Prescription Drug Maker Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the chronic therapy drug maker shares on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.<\/p>\n<p>In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%.<\/p>\n<p>Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P\/E of 23.5, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.<\/p>\n<p><strong>What to watch:<\/strong> Check how smoothly acquired brands are integrated and how the injectables unit scales.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Mankind_Pharma_Features_Among_These_Branded_Prescription_Drug_Maker_Stocks\"><\/span><strong>Why Mankind Pharma Features Among These Branded Prescription Drug Maker Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Mankind Pharma is one of India&#8217;s largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.<\/p>\n<p>The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P\/E of 45.0, above the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.<\/p>\n<p><strong>What to watch:<\/strong> Watch the market share in chronic therapies and the integration of acquired brands.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Torrent_Pharmaceuticals_vs_Eris_Lifesciences_vs_Mankind_Pharma_on_Key_Financials\"><\/span><strong>Torrent Pharmaceuticals vs Eris Lifesciences vs Mankind Pharma on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three branded prescription drug maker stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Torrent Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,705<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13,886<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,138<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Eris Lifesciences<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,373<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,137<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">648<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mankind Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,978<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,636<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,938<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Mankind Pharma has the largest FY26 revenue at Rs 14,636 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with branded prescription drug maker stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Torrent Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,141<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,909<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">56.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Eris Lifesciences<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">776<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">876<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mankind Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,650<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,076<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.7%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Branded_Prescription_Drug_Maker_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Branded Prescription Drug Maker Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these branded prescription drug maker stocks, the main points are: Long-term chronic therapy drug maker shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Price controls.<\/strong> Government pricing rules can affect some medicines.<\/li>\n<li><strong>Competition.<\/strong> Many companies compete for doctor attention.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter branded prescription drug maker stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Branded_Prescription_Drug_Maker_Stocks\"><\/span><strong>Final Thoughts on Branded Prescription Drug Maker Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Branded prescription drug maker stocks reward investors who follow demand trends, order books and margins together. Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma each have a clear plan to grow their brands. Based on the 23 October 2026 close, Torrent Pharmaceuticals trades at Rs 4,524.4, Eris Lifesciences at Rs 1,095.5 and Mankind Pharma at Rs 2,212.6. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these branded prescription drug maker stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track branded prescription drug maker stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_branded_prescription_drug_maker_stocks\"><\/span><strong>What are branded prescription drug maker stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Branded prescription drug maker stocks are listed drug makers that sell prescription and consumer health brands to doctors and patients across India. Their earnings depend on brand strength, field force reach, new launches and the share of chronic therapies. This list looks at three of them, Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_branded_prescription_drug_maker_stocks_are_covered_in_this_list\"><\/span><strong>Which branded prescription drug maker stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma. Based on the 23 October 2026 close, Torrent Pharmaceuticals traded at Rs 4,524.4, Eris Lifesciences at Rs 1,095.5 and Mankind Pharma at Rs 2,212.6. Their return on equity ranges from 11.7% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 22.9%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_branded_prescription_drug_maker_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do branded prescription drug maker stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Branded prescription drug maker stocks have a strong roadmap in India because rising healthcare access, longer life spans and a growing chronic disease burden keep lifting demand for trusted branded medicines. The main drivers are as follows. Chronic therapies. Long-term treatments for heart, diabetes and stomach care give repeat demand. Field force reach. Large doctor networks help new launches scale. Consumer health. Trusted over-the-counter brands widen the customer base. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Torrent_Pharmaceuticals_performed_financially\"><\/span><strong>How has Torrent Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P\/E of 80.3, above the industry P\/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Eris_Lifesciences_performed_financially\"><\/span><strong>How has Eris Lifesciences performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P\/E of 23.5, below the industry P\/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Mankind_Pharma_performed_financially\"><\/span><strong>How has Mankind Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P\/E of 45.0, above the industry P\/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_branded_prescription_drug_maker_stocks\"><\/span><strong>What risks should investors check before buying branded prescription drug maker stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying branded prescription drug maker stocks. Price controls. Government pricing rules can affect some medicines. Competition. Many companies compete for doctor attention. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_branded_prescription_drug_maker_stocks_investment_advice\"><\/span><strong>Is this list of branded prescription drug maker stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are branded prescription drug maker stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Branded prescription drug maker stocks are listed drug makers that sell prescription and consumer health brands to doctors and patients across India. Their earnings depend on brand strength, field force reach, new launches and the share of chronic therapies. This list looks at three of them, Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which branded prescription drug maker stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma. Based on the 23 October 2026 close, Torrent Pharmaceuticals traded at Rs 4,524.4, Eris Lifesciences at Rs 1,095.5 and Mankind Pharma at Rs 2,212.6. Their return on equity ranges from 11.7% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 22.9%.\"}},{\"@type\":\"Question\",\"name\":\"Why do branded prescription drug maker stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Branded prescription drug maker stocks have a strong roadmap in India because rising healthcare access, longer life spans and a growing chronic disease burden keep lifting demand for trusted branded medicines. The main drivers are as follows. Chronic therapies. Long-term treatments for heart, diabetes and stomach care give repeat demand. Field force reach. Large doctor networks help new launches scale. Consumer health. Trusted over-the-counter brands widen the customer base. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Torrent Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P\/E of 80.3, above the industry P\/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.\"}},{\"@type\":\"Question\",\"name\":\"How has Eris Lifesciences performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P\/E of 23.5, below the industry P\/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.\"}},{\"@type\":\"Question\",\"name\":\"How has Mankind Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P\/E of 45.0, above the industry P\/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying branded prescription drug maker stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying branded prescription drug maker stocks. Price controls. Government pricing rules can affect some medicines. Competition. Many companies compete for doctor attention. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of branded prescription drug maker stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Branded Prescription Drug Maker Stocks with a strong future roadmap: Torrent Pharmaceuticals, Eris Lifesciences and Mankind Pharma. Compare price, valuation, return on equity and revenue growth as of 23 October 2026.<\/p>\n","protected":false},"author":35,"featured_media":326340,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,15847,15848,13903,805,15849,13963],"class_list":["post-326341","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-branded-prescription-drug-maker-stocks","tag-chronic-therapy-drug-maker-shares","tag-eris-lifesciences","tag-mankind-pharma","tag-prescription-brand-company-stocks","tag-torrent-pharmaceuticals"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["326340"],"rank_math_title":["Domestic Branded Pharma Stocks"],"rank_math_description":["Compare 3 branded prescription drug maker stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 23 Oct 2026."],"rank_math_focus_keyword":["branded prescription drug maker stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-cardiovascular-and-cns-leader-chronic-therapy-specialist-and-largest-domestic.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/326341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=326341"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/326341\/revisions"}],"predecessor-version":[{"id":326342,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/326341\/revisions\/326342"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/326340"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=326341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=326341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=326341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}